ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

CD Genomics RNA-Solutions Platform Unveils m7G MeRIP Sequencing for Scientific Research

By: Get News

New York, USA - December 26, 2022 - RNA-Solutions is a platform for revolutionary research in RNA, targeting coding and non-coding RNAs with different physiological functions. Scientists at CD Genomics are ready to help detect various types of RNAs via meticulous and integrative approaches. Recently, the company has launched m7G MeRIP sequencing to detect and analyze m7G RNA modification in a single sample, providing a powerful tool for research on intracellular translation, regulation, and protein modifications.

RNA modifications refer to various chemical modifications (more than 160 types) that occur on RNA molecules, each of which has a corresponding function, such as structure stabilization, extranuclear transport, alternative splicing, translation recognition, etc. Among them, methylation modification is one of the major forms, accounting for about 2/3 of modifications. The methylation modification of RNA is mostly located on the mRNA, tRNA, rRNA and other non-coding RNA. Among them, m7G modification (N7-methyladenosine) is a kind of RNA methylation modification resulting in a positive charge. Under the action of methyltransferase, the 7th nitrogen atom of RNA guanine (G) is chemically modified with a methyl group, resulting in m7G methylation modification.

m7G RNA methylation modification often exists in the 5' cap structure of eukaryotic mRNA, which can regulate the transfer, translation, and splicing of mRNA. In addition to the 5' cap structure, m7G also exists in the tRNA and rRNA sequences. With the wide application usage of NGS, RNA modification has been widely studied and has become a hotspot in the field of epigenetics. Meanwhile, MeRIP-seq is one of the most powerful techniques for studying m7G methylation modification.

MeRIP-seq combines MeDIP, RIP, and RNA-seq technologies to accurately detect RNA methylation across the genome and fragmented RNA samples. Then, a specific RNA methylation antibody was used to achieve the co-immunoprecipitation reaction, and the obtained methylated fragments were sequenced. At the same time, it is necessary to design a control sample (similar to ChIP-seq) to normalize the background.

Antibody immunoprecipitation-based m7G MeRIP sequencing can rapidly generate a complete transcriptome map of the internal m7G methylome in biological samples from different sources. This technique uses an m7G-specific antibody to target methylated modified fragments for library preparation, and high-throughput sequencing and peak localization were carried out for the identification of m7G modified fragments. "Our experienced technical team can comprehensively detect m7G methylation modification levels of various RNA molecules, such as mRNA, lncRNA, pri-miRNA, tRNA and rRNA, and provides professional and in-depth data analysis for m7G RNA methylation modification," commented the Vice President of CD Genomics.

About CD Genomics

CD Genomics enjoys a high reputation for sequencing, microarray analysis, library construction, and genotyping and provides reliable services to pharmaceutical and biotechnology companies, academic institutions, and government agencies.

Media Contact
Company Name: CD Genomics
Contact Person: Kiko Garcia
Email: Send Email
Phone: 1-631-259-7705
Country: United States
Website: https://www.cd-genomics.com



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.